

Christoph Kaiser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10538935/publications.pdf>

Version: 2024-02-01

143
papers

11,994
citations

66343

42
h-index

26613

107
g-index

146
all docs

146
docs citations

146
times ranked

9059
citing authors

#	ARTICLE	IF	CITATIONS
1	Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. <i>Cardiovascular Revascularization Medicine</i> , 2022, 34, 3-10.	0.8	5
2	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 186-196.	3.3	8
3	Sustained Safety and Performance of a Second-Generation Sirolimus-Eluting Absorbable Metal Scaffold: Long-Term Data of the BIOSOLVE-II First-in-Man Trial at 5 Years. <i>Cardiovascular Revascularization Medicine</i> , 2022, 38, 106-110.	0.8	11
4	Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011325.	3.9	15
5	Soluble urokinase plasminogen activator receptor and functionally relevant coronary artery disease: a prospective cohort study. <i>Biomarkers</i> , 2022, 27, 278-285.	1.9	2
6	Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial. <i>Clinical Research in Cardiology</i> , 2022, 111, 806-815.	3.3	8
7	Cardiovascular imaging following perioperative myocardial infarction/injury. <i>Scientific Reports</i> , 2022, 12, 4447.	3.3	0
8	Causes of death after treatment of small coronary artery disease with paclitaxel-coated balloons. <i>Clinical Research in Cardiology</i> , 2021, 110, 307-311.	3.3	6
9	Effect of COVID-19 on acute treatment of ST-segment elevation and Non-ST-segment elevation acute coronary syndrome in northwestern Switzerland. <i>IJC Heart and Vasculature</i> , 2021, 32, 100686.	1.1	7
10	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. <i>ESC Heart Failure</i> , 2021, 8, 1924-1932.	3.1	8
11	Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 639-648.	2.9	33
12	Incidence and outcomes of perioperative myocardial infarction/injury diagnosed by high-sensitivity cardiac troponin I. <i>Clinical Research in Cardiology</i> , 2021, 110, 1450-1463.	3.3	18
13	Proton Transfer Dynamics of Photoacidic Merocyanines in Aqueous Solution. <i>Chemistry - A European Journal</i> , 2021, 27, 9160-9173.	3.3	14
14	Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. <i>International Journal of Cardiology</i> , 2021, 334, 37-41.	1.7	2
15	Non-invasive predictors for infranodal conduction delay in patients with left bundle branch block after TAVR. <i>Clinical Research in Cardiology</i> , 2021, 110, 1967-1976.	3.3	0
16	Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1789-1798.	2.9	22
17	Impact of Atrial Fibrillation on Outcome in Takotsubo Syndrome: Data From the International Takotsubo Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e014059.	3.7	18
18	<i>In vivo</i> relationship between near-infrared spectroscopy-detected lipid-rich plaques and morphological plaque characteristics by optical coherence tomography and intravascular ultrasound: a multimodality intravascular imaging study. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 824-834.	1.2	17

#	ARTICLE	IF	CITATIONS
19	Drug-Eluting or Bare-Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization. <i>Journal of the American Heart Association</i> , 2021, 10, e018828.	3.7	4
20	Clinical correlates and prognostic impact of neurologic disorders in Takotsubo syndrome. <i>Scientific Reports</i> , 2021, 11, 23555.	3.3	13
21	Incremental value of high-frequency QRS analysis for diagnosis and prognosis in suspected exercise-induced myocardial ischaemia. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 836-847.	1.0	3
22	Drug-coated balloons in cardiovascular disease: benefits, challenges, and clinical applications. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 201-211.	5.0	20
23	Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 330-337.	7.1	24
24	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 279-287.	2.4	34
25	Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. <i>Lancet</i> , The, 2020, 396, 1504-1510.	13.7	96
26	Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents for Primary PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2314-2316.	2.9	0
27	The Interplay of Nanoconfinement and pH from the Perspective of a Dye-Reporter Molecule. <i>ChemNanoMat</i> , 2020, 6, 1843-1853.	2.8	2
28	Long-Term Results After Drug-Eluting Versus Bare-Metal Stent Implantation in Saphenous Vein Grafts: Randomized Controlled Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e017434.	3.7	7
29	Prognostic value of texture analysis from cardiac magnetic resonance imaging in patients with Takotsubo syndrome: a machine learning based proof-of-principle approach. <i>Scientific Reports</i> , 2020, 10, 20537.	3.3	9
30	Using High-Sensitivity Cardiac Troponin for the Exclusion of Inducible Myocardial Ischemia in Symptomatic Patients. <i>Annals of Internal Medicine</i> , 2020, 172, 175.	3.9	14
31	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. <i>European Heart Journal</i> , 2020, 41, 3255-3268.	2.2	49
32	A Randomized Trial of Recombinant Human C1-Esterase-Inhibitor in the Prevention of Contrast-Induced Kidney Injury. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 833-842.	2.9	10
33	Electrophysiology Testing to Stratify Patients With Left Bundle Branch Block After Transcatheter Aortic Valve Implantation. <i>Journal of the American Heart Association</i> , 2020, 9, e014446.	3.7	23
34	Drug-coated balloon versus drug-eluting stent in small coronary artery lesions: angiographic analysis from the BASKET-SMALL 2 trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1114-1124.	3.3	18
35	Age-Related Variations in Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1869-1877.	2.8	42
36	Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008024.	3.9	21

#	ARTICLE	IF	CITATIONS
37	Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010881.	3.7	63
38	Biodegradable polymer drug-eluting stent vs. contemporary durable polymer drug-eluting stents in patients with diabetes: a meta-analysis of randomized controlled trials. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 6, 81-88.	4.0	3
39	Do ultrathin strut bare-metal stents with passive coating improve efficacy in large coronary arteries? Insights from the randomized, multicenter BASKET-PROVE trials. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 226.	1.7	1
40	Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. <i>Journal of the American Heart Association</i> , 2019, 8, e013607.	3.7	17
41	Clinical Predictors and Prognostic Impact of Recovery of Wall Motion Abnormalities in Takotsubo Syndrome: Results From the International Takotsubo Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e011194.	3.7	27
42	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. <i>Circulation</i> , 2019, 139, 413-415.	1.6	75
43	Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score. <i>European Journal of Heart Failure</i> , 2019, 21, 1469-1472.	7.1	20
44	Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. <i>Lancet, The</i> , 2019, 394, 1243-1253.	13.7	138
45	Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. <i>PLoS ONE</i> , 2019, 14, e0210821.	2.5	5
46	Drug-coated balloons: room for development of BASKET-SMALL 2 – Authors' reply. <i>Lancet, The</i> , 2019, 393, 1934-1935.	13.7	0
47	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. <i>European Heart Journal</i> , 2019, 40, 2142-2151.	2.2	79
48	Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. <i>Lancet, The</i> , 2019, 393, 2503-2510.	13.7	166
49	Prevalence and determinants of exercise-induced left ventricular dysfunction in patients with coronary artery disease. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13112.	3.4	0
50	Perioperative major adverse cardiac events in urgent femoral artery repair after coronary stenting are less common than previously reported. <i>Journal of Vascular Surgery</i> , 2019, 70, 216-223.	1.1	0
51	First Report of Edge Vascular Response at 12-Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 392-398.	0.8	9
52	Drug-eluting stents in large coronary vessels improve both safety and efficacy compared with bare-metal stents in women: a pooled analysis of the BASKET-PROVE I and II trials. <i>Open Heart</i> , 2019, 6, e000986.	2.3	4
53	Clinical utility of circulating interleukin-6 concentrations in the detection of functionally relevant coronary artery disease. <i>International Journal of Cardiology</i> , 2019, 275, 20-25.	1.7	10
54	A light-responsive RNA aptamer for an azobenzene derivative. <i>Nucleic Acids Research</i> , 2019, 47, 2029-2040.	14.5	23

#	ARTICLE	IF	CITATIONS
55	Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2. <i>Clinical Cardiology</i> , 2018, 41, 569-575.	1.8	13
56	Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 867-873.	1.7	4
57	Prospective Validation of a Biomarker-Based Rule Out Strategy for Functionally Relevant Coronary Artery Disease. <i>Clinical Chemistry</i> , 2018, 64, 386-395.	3.2	30
58	Prasugrel vs clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts – Response to the letter to the Editor. <i>International Journal of Cardiology</i> , 2018, 251, 33.	1.7	0
59	Perioperative Myocardial Injury After Noncardiac Surgery. <i>Circulation</i> , 2018, 137, 1221-1232.	1.6	337
60	Combining high-sensitivity cardiac troponin and B-type natriuretic peptide in the detection of inducible myocardial ischemia. <i>Clinical Biochemistry</i> , 2018, 52, 33-40.	1.9	13
61	Supra-annular sizing for transcatheter valve implantation in bicuspid aortic stenosis. <i>Postępy W Kardiologii Interwencyjnej</i> , 2018, 14, 187-190.	0.2	5
62	Direct Comparison of Cardiac Troponin T and I Using a Uniform and a Sex-Specific Approach in the Detection of Functionally Relevant Coronary Artery Disease. <i>Clinical Chemistry</i> , 2018, 64, 1596-1606.	3.2	19
63	Long-Term Prognosis of Patients With Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 72, 874-882.	2.8	224
64	Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. <i>Lancet, The</i> , 2018, 392, 737-746.	13.7	101
65	Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. <i>Lancet, The</i> , 2018, 392, 849-856.	13.7	263
66	A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. <i>EuroIntervention</i> , 2018, 14, 692-699.	3.2	11
67	Long-term outcomes in patients with rheumatologic disorders undergoing percutaneous coronary intervention: a BAsel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination (BASKET-PROVE) sub-study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 778-786.	1.0	10
68	Thermal, Photochromic and Dynamic Properties of Water-Soluble Spiropyran. <i>ChemistrySelect</i> , 2017, 2, 4111-4123.	1.5	23
69	Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts. <i>International Journal of Cardiology</i> , 2017, 248, 20-27.	1.7	5
70	Pyridine-Spiropyran Derivative as a Persistent, Reversible Photoacid in Water. <i>Journal of Organic Chemistry</i> , 2017, 82, 8040-8047.	3.2	36
71	Frequency of Cardiac Death and Stent Thrombosis in Patients With Chronic Obstructive Pulmonary Disease Undergoing Percutaneous Coronary Intervention (from the BASKET-PROVE I and II Trials). <i>American Journal of Cardiology</i> , 2017, 119, 14-19.	1.6	12
72	Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents – A clinical and health-economic evaluation. <i>Cardiovascular Therapeutics</i> , 2017, 35, 19-25.	2.5	18

#	ARTICLE	IF	CITATIONS
73	Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 994-1002.	1.7	9
74	First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study. <i>Postepy W Kardiologii Interwencyjnej</i> , 2016, 4, 314-320.	0.2	6
75	Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 981-983.	2.9	7
76	Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. <i>European Heart Journal</i> , 2016, 37, 2701-2709.	2.2	149
77	Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. <i>European Heart Journal</i> , 2016, 37, 2823-2829.	2.2	136
78	Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial. <i>Journal of the American Heart Association</i> , 2016, 5, e003255.	3.7	50
79	Incidence and Predictors of Cardiomyocyte Injury in Elective Coronary Angiography. <i>American Journal of Medicine</i> , 2016, 129, 537.e1-537.e8.	1.5	4
80	Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trial. <i>American Heart Journal</i> , 2016, 173, 1-7.	2.7	4
81	Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. <i>Lancet, The</i> , 2016, 387, 31-39.	13.7	284
82	Angiographic complexity of coronary artery disease according to SYNTAX score and clinical outcomes after revascularisation with newer-generation drug-eluting stents: a substudy of the BIOSCIENCE trial. <i>EuroIntervention</i> , 2016, 12, e595-e604.	3.2	11
83	Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction. <i>EuroIntervention</i> , 2016, 12, e1343-e1354.	3.2	27
84	Long-Term Efficacy and Safety of Biodegradable-Polymer Biolimus-Eluting Stents. <i>Circulation</i> , 2015, 131, 74-81.	1.6	87
85	Reduction of ST-elevation myocardial infarction in Canton Ticino (Switzerland) after smoking bans in enclosed public places – No Smoke Pub Study. <i>European Journal of Public Health</i> , 2015, 25, 195-199.	0.3	8
86	Paclitaxel-eluting versus bare metal stents in primary PCI: a pooled patient-level meta-analysis of randomized trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 101-112.	2.1	7
87	Clinical Outcomes According to Diabetic Status in Patients Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	3.9	29
88	Prasugrel Increases the Need for Platelet Transfusions and Surgical Reexploration Rates Compared with Clopidogrel in Coronary Artery Bypass Surgery. <i>Thoracic and Cardiovascular Surgeon</i> , 2015, 63, 028-035.	1.0	14
89	Improved outcomes of elderly patients treated with drug-eluting versus bare metal stents in large coronary arteries: Results from the BAsel Stent Kosten-EffektivitÄts Trial PROspective Validation Examination randomized trial. <i>American Heart Journal</i> , 2015, 170, 787-795.e1.	2.7	11
90	Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. <i>New England Journal of Medicine</i> , 2015, 373, 929-938.	27.0	1,827

#	ARTICLE	IF	CITATIONS
91	Abstract 16776: Drug-eluting Stents in Large Coronary Vessels Improve Both Safety and Efficacy in Women Compared to Bare-metal Stents. <i>Circulation</i> , 2015, 132, .	1.6	0
92	Abstract 16775: Efficacy and Safety of a Thinner-strut Silicon Carbide-coated Cobalt Chromium Bare-metal Stent Compared to a Thin-strut Uncoated Cobalt Chromium Bare-metal Stent in Large Vessel Stenting: Insights From Two Prospective Randomised All-comers Trials. <i>Circulation</i> , 2015, 132, .	1.6	0
93	Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. <i>BMJ, The</i> , 2014, 349, g6427-g6427.	6.0	82
94	Pacemaker Implantation and Need for Ventricular Pacing during Follow-up after Transcatheter Aortic Valve Implantation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 1592-1601.	1.2	37
95	Impact of hypertension on clinical outcome in STEMI patients undergoing primary angioplasty with BMS or DES. <i>International Journal of Cardiology</i> , 2014, 175, 50-54.	1.7	20
96	Prognostic Value of Routine Cardiac Stress Imaging 5 Years After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 615-621.	2.9	25
97	Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents. <i>Journal of the American College of Cardiology</i> , 2014, 63, 299-307.	2.8	269
98	Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. <i>Lancet, The</i> , 2014, 384, 2111-2122.	13.7	224
99	Drug-eluting stents with biodegradable polymers: are enough data in for a final assessment?. <i>European Heart Journal</i> , 2014, 35, 1098-1100.	2.2	2
100	Drug-eluting stents in patients with anterior STEMI undergoing primary angioplasty: a substudy of the DESERT cooperation. <i>Clinical Research in Cardiology</i> , 2014, 103, 685-699.	3.3	4
101	Sirolimus-eluting versus paclitaxel-eluting stent in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 355-363.	2.1	5
102	Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: Rationale and design of the BIOSCIENCE trial. <i>American Heart Journal</i> , 2014, 168, 256-261.	2.7	16
103	Single-Center Experience and Short-term Outcome with the JenaValve: A Second-Generation Transapical Transcatheter Aortic Valve Implantation Device. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2014, 9, 368-374.	0.9	1
104	Gender-related differences in outcome after BMS or DES implantation in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: Insights from the DESERT cooperation. <i>Atherosclerosis</i> , 2013, 230, 12-16.	0.8	15
105	Heart rate at discharge and long-term prognosis following percutaneous coronary intervention in stable and acute coronary syndromes results from the BASKET PROVE trial. <i>International Journal of Cardiology</i> , 2013, 168, 3802-3806.	1.7	26
106	Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease. <i>International Journal of Cardiology</i> , 2013, 168, 2381-2388.	1.7	15
107	Clinical Outcomes With Drug-Eluting and Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 62, 496-504.	2.8	210
108	Impact of Age on Long-Term Outcome After Primary Angioplasty With Bare-Metal or Drug-Eluting Stent (from the DESERT Cooperation). <i>American Journal of Cardiology</i> , 2013, 112, 181-186.	1.6	31

#	ARTICLE	IF	CITATIONS
109	Impact of Diabetes on Long-Term Outcome After Primary Angioplasty. <i>Diabetes Care</i> , 2013, 36, 1020-1025.	8.6	91
110	Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. <i>Thrombosis and Haemostasis</i> , 2013, 110, 826-833.	3.4	62
111	No One-Size-Fits-All. <i>Circulation</i> , 2012, 125, 471-473.	1.6	8
112	Response to Letter Regarding Article, "Stent Thrombosis with Everolimus-Eluting Stents: Meta-Analysis of Comparative Randomized Controlled Trials". <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, .	3.9	0
113	Drug-Eluting vs Bare-Metal Stents in Primary Angioplasty. <i>Archives of Internal Medicine</i> , 2012, 172, 611-21; discussion 621-2.	3.8	218
114	Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. <i>Lancet</i> , The, 2012, 379, 1393-1402.	13.7	854
115	Stent Thrombosis With Everolimus-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 357-364.	3.9	140
116	Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: The Basel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. <i>American Heart Journal</i> , 2012, 163, 136-141.e1.	2.7	15
117	Coronary Artery Disease Progression Late After Successful Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2012, 59, 793-799.	2.8	58
118	No One-Size-Fits-All. <i>Circulation</i> , 2011, , 1.	1.6	0
119	The BASKET study program: continued evaluation of the efficacy and safety of drug-eluting stents. <i>Interventional Cardiology</i> , 2011, 3, 461-466.	0.0	1
120	Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. <i>Clinical Research in Cardiology</i> , 2010, 99, 345-357.	3.3	34
121	Drug-Eluting versus Bare-Metal Stents in Large Coronary Arteries. <i>New England Journal of Medicine</i> , 2010, 363, 2310-2319.	27.0	243
122	Drug-Eluting Stents Compared with Bare Metal Stents Improve Late Outcome after Saphenous Vein Graft but Not after Large Native Vessel Interventions. <i>Cardiology</i> , 2009, 112, 49-55.	1.4	57
123	Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2009, 133, 213-222.	1.7	89
124	Drug-Eluting Stents Versus Bare-Metal Stents in Diabetic Patients With ST-Segment Elevation Acute Myocardial Infarction: A Pooled Analysis of Individual Patient Data From 7 Randomized Trials. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 354-364.	0.6	10
125	The Balance of Risks and Benefits of Drug-Eluting Versus Bare-Metal Stents. <i>Journal of the American College of Cardiology</i> , 2008, 51, 972.	2.8	1
126	Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective) Tj ETQq0 0 0,rgBT /Overlock 10	2.78	26

#	ARTICLE	IF	CITATIONS
127	Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. <i>European Heart Journal</i> , 2008, 30, 16-24.	2.2	99
128	Value and Limitations of Target-Vessel Ischemia in Predicting Late Clinical Events After Drug-Eluting Stent Implantation. <i>Journal of Nuclear Medicine</i> , 2008, 49, 550-556.	5.0	24
129	Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. <i>European Heart Journal</i> , 2007, 28, 2706-2713.	2.2	337
130	Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. <i>New England Journal of Medicine</i> , 2007, 356, 1030-1039.	27.0	1,182
131	Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis. <i>Lancet, The</i> , 2007, 370, 1552-1559.	13.7	91
132	Targeted stent use in clinical practice based on evidence from the BAseL Stent Cost Effectiveness Trial (BASKET). <i>European Heart Journal</i> , 2007, 28, 719-725.	2.2	74
133	A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1373-1380.	2.8	307
134	Effectiveness and safety of paclitaxel-eluting stents in patients with ST-segment elevation acute myocardial infarction. <i>EuroIntervention</i> , 2007, 3, 386-391.	3.2	9
135	Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2584-2591.	2.8	1,242
136	Paclitaxel-eluting stents appear to reduce revascularisation in people with long lesions. <i>Evidence-based Cardiovascular Medicine</i> , 2006, 10, 49-51.	0.0	0
137	Long-Term Benefits and Limitations of Combined Antianginal Drug Therapy in Elderly Patients with Symptomatic Chronic Coronary Artery Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005, 10, 29-37.	2.0	5
138	Limited diagnostic yield of non-invasive coronary angiography by 16-slice multi-detector spiral computed tomography in routine patients referred for evaluation of coronary artery disease. <i>European Heart Journal</i> , 2005, 26, 1987-1992.	2.2	62
139	Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). <i>Lancet, The</i> , 2005, 366, 921-929.	13.7	322
140	Vascular Responses at Proximal and Distal Edges of Paclitaxel-Eluting Stents. <i>Circulation</i> , 2004, 109, 627-633.	1.6	114
141	Risks and benefits of optimised medical and revascularisation therapy in elderly patients with angina ? on-treatment analysis of the TIME trial. <i>European Heart Journal</i> , 2004, 25, 1036-1042.	2.2	33
142	Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). <i>European Heart Journal</i> , 2004, 25, 2195-2203.	2.2	47
143	Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting. <i>Journal of the American College of Cardiology</i> , 2003, 42, 33-40.	2.8	100